Gilead Sciences Reports Quarterly Earnings Growth of 55%

Gilead Sciences said on Wednesday its first-quarter profit rose 55% amid higher sales of its drugs for HIV, the virus that causes AIDS.

The biotechnology company said net income rose to $407.4 million, or 85 cents a share, from $262.7 million, or 55 cents a share, a year earlier. Analysts expected a profit of 80 cents a share.

"It's another solid quarter for Gilead ... they keep putting up great numbers," said analyst Michael King of Rodman & Renshaw.

The company continues to expect full-year 2007 drug sales of $3.4 billion to $3.5 billion, Chief Financial Officer John Milligan said on a conference call.

"We would prefer to wait until the end of the second quarter to update the guidance," he said, noting first-quarter sales of anti-fungal drug Ambisome and hepatitis drug Hepsera were stronger than the company had expected.

Total revenue rose 48% to $1.03 billion, exceeding the $992.7 million forecast by analysts.

Sales of HIV drugs rose 56% to $705.1 million, including $345.9 million for the two-drug combination HIV pill Truvada, and $190.2 million for Atripla, a once-daily pill approved by U.S. regulators last July that layers Truvada with Bristol-Myers Squibb's Sustiva.

First-quarter sales of Viread and Emtriva, the two older HIV drugs used in the combination pills, fell 16% to $160.7 million and by 16% to $8.3 million, respectively, as patients switched to the newer treatments.

Hepsera sales rose 35% to $71.3 million, while Ambisome sales rose 14% to $61.5 million.

Foster City, California,-based Gilead also collects royalties on sales by Roche for Tamiflu, an antiviral treatment being stockpiled as a potential treatment for bird flu.

First-quarter royalty and contract revenue more than tripled to $188.2 million, including $167.9 million from Roche for fourth-quarter 2006 Tamiflu sales.

The company said quarterly research and development costs rose to $130.1 million from $88.4 million, while sales and administrative expense rose to $166.6 million from $142.5 million.

Gilead is awaiting a June decision from the U.S. Food and Drug Administration on its application for ambrisentan, a drug developed by Myogen for the treatment of pulmonary arterial hypertension. If approved, the drug could generate annual sales of more than $1 billion, analysts estimate.

Gilead's shares are up more than 21% so far this year, compared with a gain of nearly 8% for the AMEX Biotech Index. The stock, which closed at $78.43, was up slightly in after hours trading.

Contact U.S. News


    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More

Don't Miss

U.S. Video